Avadel Pharmaceuticals Plc Sponsored ADR AVDL 深 沪
已收盘 08-01 16:00:00 美东时间
11.08
+0.570
+5.42%
华盛通- 最 高11.12
- 今 开10.53
- 成交量 99.34万股
- 最 低 10.42
- 昨 收 10.51
- 总市值 10.74亿
- 52周最高 16.84
- 市盈率 静 --
- 换手率 1.03%
- 52周最低 6.38
- 委 比 61.51%
- 总股本 9690.05万
- 历史最高 19.09
- 量 比 1.39
- 振 幅 6.66%
- 历史最低 1.03
- 每 手 1
- 风险率 1.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
Avadel Pharmaceuticals will host a conference call on August 7, 2025, at 8:30 a.m. ET to discuss its second-quarter 2025 financial results. A live webcast and replay will be available on the company’s website, www.avadel.com. Participants can register for the call in advance. The company operates in the biopharmaceutical sector and markets LUMRYZ™, its FDA-approved treatment for narcolepsy.
07-31 12:00
HC Wainwright & Co. Assumes Avadel Pharmaceuticals at Buy, Announces Price Target of $22
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy rating and announces Price Target of $22.
07-18 18:36
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options
07-02 01:28
Avadel Board Under Fire as ASL Strategic Value Cites Governance Failures
Avadel Pharmaceuticals ($AVDL) is facing mounting pressure from activist invest...
06-30 16:23
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
Avadel Pharmaceuticals' LUMRYZ, a once-at-bedtime oxybate treatment for narcolepsy, has received FDA approval and appellate court affirmation, underscoring its clinical superiority. The drug improves excessive daytime sleepiness and cataplexy, with benefits supported by clinical trials. Avadel plans to expand LUMRYZ's accessibility, aiming to enhance patient care for narcolepsy patients.
06-30 11:00
Avadel Pharmaceuticals Announces Appeals Court Unanimously Upholds FDA Approval Of LUMRYZ
As previously disclosed, on June 22, 2023, Jazz Pharmaceuticals, Inc. ("Jazz") filed an Administrative Procedure Act ("APA") suit against the U.S. Food and Drug Administration (the "FDA"), the U.S. Department
06-28 04:08
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals announced that its Compensation Committee approved the grant of non-statutory options to two new employees and Susan Rodriguez, the newly appointed Chief Operating Officer, to purchase 9,600 and 300,000 ordinary shares, respectively, under the 2021 Inducement Plan. The awards were granted as inducements for employment, with options vesting over four years and valid for ten years. Avadel, a biopharmaceutical company, focuses...
06-16 20:05
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Avadel Pharmaceuticals' drug LUMRYZ has received U.S. FDA Orphan Drug Designation for treating Idiopathic Hypersomnia (IH), a rare sleep disorder, based on its potential as a once-nightly treatment. The designation supports orphan drug exclusivity upon approval. Phase 3 trial enrollment is ongoing, targeting 150 IH patients.
06-05 11:30
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
LUMRYZ在SLEEP 2025会议上展示的临床和真实世界数据显示其显著改善嗜睡症患者过度日间睡眠和猫aplexy。 interim REFRESH研究显示从两次夜间服用转为一次夜间服用LUMRYZ的患者白天困倦明显减少，ESS评分恢复正常。此外，LUMRYZ在REST-ON试验中对睡眠窒息指数和睡眠中断有显著改善，并且长期耐受性良好。
05-29 20:05
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 10:30 a.m. ET. A live webcast and recording of the event will be available on Avadel’s Investor Relations website for 90 days. The company specializes in innovative solutions for medication development, with LUMRYZ™ as its approved product for narcolepsy treatment.
05-29 12:00
